BBK Worldwide^® Blog

The clinical trial landscape saw a lot of changes in 2021, from decentralized clinical trial adoption to a greater emphasis on diversity and inclusion. But what’s in store for 2022? We asked our industry experts to weigh in with their predictions.

New survey results and insights help clinical trial sponsors improve diversity and inclusion, enroll faster, and keep participants engaged longer.

When we developed our latest Study Voices survey, we expected to see large gaps in attitudes and experiences among healthcare consumers and clinical trial participants based on factors such as age, race, ethnicity, gender, and income – but that wasn’t the case.

Catch Up on Our Content for Clinical Trial Sponsors

Now is the perfect time to catch up on our most popular content of 2021!

Featuring insights from industry thought leaders, our content provides clinical trial sponsors with knowledge and guidance to help navigate today’s challenging clinical trial enrollment and engagement landscape.

The One Thing Every Sponsor Needs to Start a Decentralized Clinical Trial Off Right

I recently sat down with Chief Innovation Officer Rob Laurens to discuss how BBK's Engagement Solution Center solves many of the challenges sponsors face when planning and initiating a decentralized clinical trial. 

Earlier this week, Cellectar Biosciences, a late-stage clinical biopharmaceutical company focused on the discovery and development of targeted drugs for the treatment of cancer, announced its partnership with BBK to provide concierge services for patients participating in its clinical studies. The services are designed to improve patients' and their caregivers' access to high-quality care and innovative treatments for their cancer.

Earlier this week, BBK's Senior Director of Patient Engagement Services Mike Johnson spoke with Outsourcing-Pharma to discuss the RSG^® Arrive travel program and its recent milestone of 20,000 completed trips.

In this in-depth interview, Mike discusses what sets this program apart from others as he highlights the concierge specialists who are experienced in understanding all the ramifications of a request, as it relates not only to arranging a travel itinerary but also ensuring the itinerary supports patient health, safety, and compliance. In addition, Mike shares insight into the significance of the milestone for BBK as well as the industry at large. Click here to read the full article.

Getting Decentralized Right

What Matters to Patients

In Part 2 of our two-part interview with Phil Kelly, we delve further into the patient perspective on decentralized clinical trials. We ask Phil Kelly to share his thoughts on patient needs, tools, technologies, and the patient experience.

If you are conducting a decentralized clinical trial or planning for one, this is a must-see segment, with valuable insight to leverage for success.

RSG® Arrive Reaches Milestone of 20,000 Completed Trips

Enrollment, Engagement, and Satisfaction Data Confirms That Extending Study Support Beyond the Care Setting Yields Positive Results

Launched in 2012, RSG® Arrive has made clinical trial participation possible for thousands of patients worldwide. Today, the program has reached a major milestone with the completion of 20,000 trips. 

Getting Decentralized Right

What Matters to Patients

We know the industry is ready to embrace decentralized clinical trials. But what about patients? What do they think about decentralized clinical trials? What elements are important to them? And what should sponsors consider when designing such trials?

To dig deep, we spoke one-on-one with Phil Kelly, a bladder cancer patient and advocate. He shares his experience and insight in Part 1 of this two-part series on the patient perspective.

Each year members of the industry gather together at Dpharm — a conference which challenges attendees to question how we, as an industry, can disrupt clinical research to reduce the burden to patients and physicians. This year's event will be held virtually September 28-29 and will focuses on making innovation stick in a post-COVID world.